Results 1 to 10 of about 20,950 (257)

Secukinumab

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks.
Nilgün Atakan
doaj   +9 more sources

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

Arthritis Research & Therapy, 2023
Background Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here.
Juergen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip Van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Désirée van der Heijde, Tingting Zhuang, Anna Stefanska, Aimee Readie, Hanno B. Richards, Atul Deodhar   +14 more
doaj   +2 more sources

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Frontiers in Pharmacology, 2022
Purpose: Secukinumab was approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, the long-term safety of secukinumab in large sample population was unknown.
Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He, Qilin Zhang   +5 more
doaj   +2 more sources

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)

RMD Open, 2023
Background Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate.
Maxime Dougados, Pascal Claudepierre, Adeline Ruyssen-Witrand, Philippe Goupille, Alain Saraux, Anne Tournadre, Daniel Wendling, Cédric Lukas, Julien Lucas, Emilie Desfleurs   +9 more
doaj   +2 more sources

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study

Indian Journal of Dermatology
Background: Overweight and obesity are common in patients with psoriasis and are associated with increased disease severity and declined treatment response.
Xiuqiu Lin, Min Ou, Yang Li, Junjie Lin, Yunling Yan, Xiaohua Wang   +5 more
doaj   +2 more sources

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

New England Journal of Medicine, 2014
Mark G Lebwohl, Kristian Reich, Christopher Em Griffiths   +2 more
exaly   +2 more sources

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens

Clinics, 2021
The appropriate dosing regimens of secukinumab for psoriatic arthritis (PsA) are not well defined. We performed a meta-analysis to evaluate the efficacy and safety of different dosing regimens of secukinumab in the treatment of PsA.
Kai-Lin Zhang, Si-Yuan Hou, Dan Wu
doaj   +1 more source

Secukinumab in psoriasis: A single-center experience

Turkderm Turkish Archives of Dermatology and Venereology, 2021
Background and Design: Several randomized clinical trials demonstrated the safety and efficacy of secukinumab in the systemic treatment of moderate-severe psoriasis; however, real-life data is limited.
Esra Ağaoğlu, Hilal Kaya Erdoğan, Ersoy Acer, Zeynep Nurhan Saraçoğlu, Muzaffer Bilgin   +4 more
doaj   +1 more source

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To assess the clinical efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis. Methods Ninety-one patients with nail psoriasis from our hospital were randomly divided into cyclosporin group (30 cases),
Zhanhan TANG, Sushan LI, Sha LV, Zhao HUANG, Zhe LIU, Fuqiu LI   +5 more
doaj   +1 more source

Secukinumab [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada, Danial E, Baker, Shannon G, Panther, Kyle Ingram, PharmD   +3 more
openaire   +2 more sources